Virpax Pharmaceuticals, Inc. (VRPX) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of May 30, 2026, Virpax Pharmaceuticals, Inc. (VRPX) trades at a price-to-earnings ratio of 0.0x, with a stock price of $0.00 and trailing twelve-month earnings per share of $-2.84.
Compared to the Healthcare sector median P/E of 22.7x, VRPX trades at a 100% discount to its sector peers. The sector includes 236 companies with P/E ratios ranging from 0.0x to 188.5x.
Relative to the broader market, VRPX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VRPX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VRPX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
VRPX P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $913M | 145.1 | - | +107%Best | |
| $385B | 91.8 | - | -1% | |
| $149B | 19.2 | - | -4% | |
| $293B | 16.3Lowest | 0.77 | +8% | |
| $31B | 23.2 | 0.57Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
What if you invested $1,000 in VRPX back in 2026?
Total return with dividends reinvested · 0+ years of data
Calculate ReturnsHow much would $100/month in VRPX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs VRPX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationVRPX vs DBVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs DBV Technologies S.A..
Compare NowVRPX — Frequently Asked Questions
Quick answers to the most common questions about buying VRPX stock.
What is VRPX's P/E ratio?
Virpax Pharmaceuticals, Inc. (VRPX) trailing twelve-month P/E ratio is 0.0x, based on TTM diluted EPS of $-2.84. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is VRPX stock overvalued or undervalued?
VRPX current P/E: 0.0x. 5-year average P/E: N/A. Percentile: N/A.
Is VRPX stock expensive?
VRPX is fairly valued relative to its own history. The current P/E of 0.0x is near the 5-year average of N/A (N/A percentile of historical range).
What is VRPX's historical P/E range?
Over the past 5 years, VRPX's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of 0.0x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does VRPX's P/E compare to the S&P 500?
VRPX current P/E: 0.0x. S&P 500 median P/E: 25.2x.
How does VRPX's valuation compare to Healthcare peers?
Virpax Pharmaceuticals, Inc. P/E of 0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is VRPX's PEG ratio?
VRPX PEG ratio is N/A, based on a P/E of 0.0x and EPS growth of -446.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is VRPX's earnings yield?
VRPX earnings yield is N/A, the inverse of its 0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.